Venus Remedies Ltd Valuation Shifts Signal Changing Market Sentiment

Valuation Metrics: Current Standing and Historical Context

As of 1 February 2026, Venus Remedies Ltd trades at ₹823.00, up 4.89% on the day from a previous close of ₹784.65. The stock is near its 52-week high of ₹848.90, a significant recovery from its 52-week low of ₹275.00. This price appreciation has contributed to the recalibration of its valuation grade from very attractive to fair, as assessed by MarketsMOJO’s proprietary scoring system.

The company’s current P/E ratio stands at 14.42, a figure that, while still reasonable, is elevated compared to its historical lows and relative to some peers. The P/BV ratio is 1.85, indicating that the stock is trading at nearly twice its book value. These metrics suggest that the market has re-rated Venus Remedies, reflecting improved investor confidence but also a reduction in the margin of safety that previously characterised the stock.

Comparative Analysis with Peers

When benchmarked against its peer group within the Pharmaceuticals & Biotechnology sector, Venus Remedies’ valuation appears balanced but less compelling than before. For instance, Shukra Pharmaceuticals is classified as very expensive with a P/E ratio exceeding 148 and an EV/EBITDA multiple of 145.09, signalling a highly stretched valuation. Conversely, Fermenta Biotec remains very attractive with a P/E of 8.46 and EV/EBITDA of 6.95, underscoring a more conservative market pricing.

Other peers such as Kwality Pharma and Lincoln Pharma are rated fair and attractive respectively, with P/E ratios of 22.45 and 11.43. Venus Remedies’ P/E of 14.42 places it comfortably between these benchmarks, suggesting a moderate valuation stance. Its EV/EBITDA multiple of 7.79 also aligns with sector averages, reinforcing the notion of a fair valuation rather than a bargain.

Financial Performance and Quality Metrics

Venus Remedies’ return on capital employed (ROCE) is a robust 19.01%, signalling efficient utilisation of capital to generate earnings. Return on equity (ROE) stands at 10.52%, a respectable figure that indicates moderate profitability relative to shareholder equity. These quality metrics support the company’s valuation, justifying a fair rating despite the upward shift in multiples.

The company’s enterprise value to capital employed ratio is 2.36, and EV to sales is 1.25, both reflecting a valuation that is not excessive relative to its operational scale. The PEG ratio, a measure of valuation relative to earnings growth, is exceptionally low at 0.08, suggesting that the stock remains undervalued when factoring in growth prospects.

Price Momentum and Market Returns

Venus Remedies has demonstrated impressive price momentum over multiple time horizons. The stock has delivered a 13.3% return over the past week and an 11.1% gain in the last month, significantly outperforming the Sensex, which rose by only 0.9% and declined by 2.84% respectively over the same periods. Year-to-date, Venus Remedies has gained 7.3%, while the Sensex has fallen 3.46%.

Longer-term returns are even more striking. Over one year, the stock has surged 178.94%, dwarfing the Sensex’s 7.18% gain. Over three and five years, Venus Remedies has delivered returns of 403.83% and 407.71%, compared to Sensex returns of 38.27% and 77.74%. Over a decade, the stock’s return of 629.61% vastly outpaces the Sensex’s 230.79%, underscoring its strong growth trajectory and investor appeal.

Valuation Grade Upgrade and Market Implications

On 28 January 2026, MarketsMOJO upgraded Venus Remedies’ Mojo Grade from Buy to Strong Buy, reflecting enhanced confidence in the company’s fundamentals and growth outlook. The Mojo Score stands at 80.0, a high rating that signals strong buy sentiment among analysts and investors alike. The market capitalisation grade is 4, indicating a mid-cap status with solid liquidity and market presence.

This upgrade coincides with the valuation grade shift from very attractive to fair, a natural consequence of the stock’s price appreciation. While the valuation is no longer a deep value proposition, the company’s operational metrics, growth potential, and relative valuation within the sector justify a premium rating.

Investor Takeaway: Balancing Valuation and Growth Prospects

Investors considering Venus Remedies should weigh the shift in valuation grade carefully. The move from very attractive to fair valuation reflects a market that has recognised the company’s growth and quality but has also priced in much of the upside. The P/E ratio of 14.42 is reasonable within the sector context, but it no longer offers the deep discount seen previously.

However, the company’s strong ROCE and ROE, combined with a very low PEG ratio, suggest that earnings growth remains robust and undervalued. The stock’s exceptional price momentum and long-term returns relative to the Sensex further reinforce its appeal as a growth-oriented investment.

Comparatively, Venus Remedies offers a more balanced risk-reward profile than some peers classified as very expensive or risky. Its valuation metrics are aligned with sector averages, making it a compelling choice for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a strong fundamental underpinning.

Conclusion

Venus Remedies Ltd’s valuation shift from very attractive to fair is a natural evolution following significant price appreciation and improved market sentiment. While the stock no longer trades at a deep value discount, its solid financial metrics, strong returns, and upgraded Mojo Grade to Strong Buy support a positive investment thesis. Investors should monitor valuation trends closely but can take comfort in the company’s robust fundamentals and sector-relative valuation standing.

Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →